Biosyent Announces Q2 and H1 2025 Financial Results
Biosyent Inc. reports robust financial results for Q2 and H1 2025, demonstrating consistent growth across its Canadian pharmaceutical, international...
Jon Napitupulu
Telix 2025 Half-Year Results: Strong Commercial Growth Fuels Long-Term Investments
Telix Pharmaceuticals reported strong H1 2025 results, with a 63% year-over-year revenue increase to $390.4 million, keeping the company...
Ascentage Pharma H1 2025: Interim Results & Updates
Ascentage Pharma’s H1 2025 results reveal a company navigating a complex transition, marked by soaring sales of its flagship...
Novo Nordisk Narrows Full-Year Sales Growth Outlook to 6-8%
Novonesis, a key player in the biosolutions market, reported robust first-half 2025 results, posting 9% organic sales growth and...
NicoX’s NCX 470 Shows Positive Phase 3 Results in Glaucoma Patients
Nicox’s positive Phase 3 DENALI trial results for NCX 470 in glaucoma patients reinforce the drug’s potential to disrupt...
Ascentage Pharma H1 2025: Mixed Financial Results, Business Updates
Ascentage Pharma’s H1 2025 results reveal a company navigating a complex landscape of commercial growth and pipeline advancement, underscored...
GenXTraits and Mendel Biotech Collaboration
GenXTraits and Mendel Biotechnology have formed a strategic partnership focused on developing next-generation crop traits, with Mendel taking a...
Novabay Pharmaceuticals Secures $6M Investment
Novabay Pharmaceuticals has secured a $6 million investment from private investor David E. Lazar, marking a pivotal shift for...
Novabay Pharmaceuticals Secures $6M Investment
Novabay Pharmaceuticals, securing a $6 million investment from private investor David E. Lazar, has opted for a strategic pivot...
Tevogen Secures $50 Million Financing for R&D and Clinical Development
Tevogen Bio Secures $50 Million Financing After Debt Elimination Tevogen Bio, a clinical-stage biotech focused on off-the-shelf T-cell therapies,...